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Abstract
Background: Pathogenic versus protective outcomes to Dengue virus (DENV) infection are associated with innate immune
function. This study aimed to determine the role of increased TLR3- and TLR7/8-mediated innate signaling after Dengue
infection of rhesus macaques in vivo to evaluate its impact on disease and anti-DENV immune responses.
Methodology/Principal Findings: TLR3 and TLR7/8 agonists (emulsified in Montanide) were administered subcutaneously
to rhesus macaques at 48 hours and 7 days after DENV infection. The Frequency and activation of myeloid dendritic cells,
plasmacytoid dendritic cells, and B cells were measured by flow cytometry while the serum levels of 14 different cytokines
and chemokines were quantified. Adaptive immune responses were measured by DENV-specific antibody subtype
measurements. Results showed that the combined TLR agonists reduced viral replication and induced the development of a
proinflammatory reaction, otherwise absent in Dengue infection alone, without any clear signs of exacerbated disease.
Specifically, the TLR-induced response was characterized by activation changes in mDC subsets concurrent with higher
serum levels of CXCL-10 and IL-1Ra. TLR stimulation also induced higher titers of anti-DENV antibodies and acted to increase
the IgG2/IgG1 ratio of anti-DENV to favor the subtype associated with DENV control. We also observed an effect of DENV-
mediated suppression of mDC activation consistent with prior in vitro studies.
Conclusions/Significance: These data show that concurrent TLR3/7/8 activation of the innate immune response after DENV
infection in vivo acts to increase antiviral mechanisms via increased inflammatory and humoral responses in rhesus
macaques, resulting in decreased viremia and melioration of the infection. These findings underscore an in vivo protective
rather than a pathogenic role for combined TLR3/7/8-mediated activation in Dengue infection of rhesus macaques. Our
study provides definitive proof-of-concept into the mechanism by which DENV evades immune recognition and activation
in vivo.
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Introduction
Dengue is the most important arboviral disease, with 50–100
million cases of Dengue Fever (DF) and 500,000 cases of Dengue
Hemorrhagic Fever (DHF)/Dengue Shock Syndrome (DSS) each
year [1]. No specific, primary or secondary prevention treatments
for Dengue are available. The disease is transmitted by either of
four dengue virus (DENV) serotypes (DENV-1, -2, -3 and -4). The
physiopathology of Dengue virus infection has been extensively
studied, and the disproportionate induction of pro-inflammatory
cytokines after infection is associated with capillary leakage and
hemorrhagic manifestations [2,3]. The importance of the adaptive
immune responses in the outcome of DENV infection is well
established [4,5]. However, more recently a key role in
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the innate immune response, particularly to the pattern-recogni-
tion receptors (PRRs) such as Toll-like receptors 7/8 (TLRs)
[6,7,8]; the retinoic acid-inducible gene/melanoma differentiation
gene 5 (RIG-I/MDA5) [9,10]; and the interaction between DENV
and the interferon signaling pathway [11,12,13]. The DENV
unfragmented, single-stranded RNA genome is recognized by
TLR7 [6,8,14], whereas double-stranded RNA (dsRNA), an
intermediary product during viral replication, can be recognized
by TLR3 [14,15]. The role of the innate immune response,
particularly of dendritic cells (DC) at early stages after DENV
infection, has become a focus of great interest [16,17,18]. Studies
in vitro show that DENV induces DC activation and maturation
[19,20]; however, the profile of activation/maturation differs
between in vitro-infected and non-infected bystander DC
[14,20,21,22]. In particular, TLR7 is implicated in the functional
response of plasmacytoid DC (pDC) to DENV [8,14] and plays an
essential role in the activation of the adaptive immune response
[23,24]. However, no study to date has explored the role of innate
activation in in vivo models of Dengue infection.
The rhesus macaque is an established non-human primate
model for the study of the innate immune response to different
viruses, including Dengue [25,26,27,28,29]. Monkeys pre-treated
with a TLR3 agonist did not die after they were challenged with a
virulent strain of yellow fever (YF). Moreover, they developed
neutralizing antibodies against YF [30]. In another study, fewer
animals treated with TLR3 agonist developed viremia or the
viremia was delayed after they were challenged with Venezuelan
Equine Encephalomyelitis (VEE) virus [31], consistent with an
antiviral role for concurrent TLR activation.
More recently, it was shown that local immunization at the
vaginal mucosa with a TLR7 agonist induced a strong innate
immune response and activation of local CD4
+ T cells in rhesus
macaques [29]. When TLR7/8 and 9 agonists, diluted in
phosphate-buffered saline (PBS) or emulsified in Montanide, an
oil-based adjuvant, were administered subcutaneously (s.c.), the
magnitude and quality of the humoral and T helper (TH) 1
cellular immune response to human immunodeficiency virus HIV
Gag protein was boosted [32,33]. Subcutaneous administration of
different TLR3 agonists in combination with an aqueous solution
of keyhole limpet hemocyanin (KLH) induced DC activation and
the stimulation of TH1 and humoral immune responses to
human papillomavirus [34]. Despite the well-established role of
combined TLR 3 or 7/8 effects in the activation of immune
responses against many viruses, little is known about their
combined role in relationship to Dengue infections in vivo.
Specifically, it has remained unknown if concurrent inflammation
by TLR activation alone after DENV infection may exacerbate
symptoms and contribute to capillary leakage and hemorrhagic
manifestations of infection or whether these clinical events are
indicative of a response involving both innate and adaptive
components.
Here, we demonstrate that combined TLR3 and 7/8
stimulation after an established DENV infection results in the
activation of myeloid DC (mDC) and in the quantitative and
qualitative modification of the adaptive immune response without
exacerbating the disease, supporting a protective role for
concurrent multi-TLR-mediated activation as in the studies noted
above. We also show that DENV is able to counteract the mDC
activation and CXCL-10 production induced by the TLR
agonists. Although TLR agonists alone were not sufficient to
induce a significant activation of B cells, in combination with
DENV they induced B-cell activation and altered the switch of
IgG classes, indicating that reductions in viral replication after
TLR agonists administration may be associated with more potent
anti-DENV responses.
Materials and Methods
Animals, virus, and procedures
Fourteen Indian rhesus macaques were stratified into compa-
rable groups based on age, weight and sex. Groups 1 (n=3;
DENV) and 2 (n=4; DENV/TLR) were infected s.c in the deltoid
area with 1 ml of 1610
4 plaque forming units (pfu) of a low-
passage Western Pacific 74 DV1 strain (Dr. L. Markoff, Walter
Reed Army Medical Center).
In addition, Group 2 animals received two doses of TLR-7/8
agonist CL097M-012 (1 mg in 200 ml/animal) and TLR3 agonist
poly (I:C) (InvivoGen, San Diego, CA) (2 mg/ml/animal) in a 70%
(v/v) emulsion of Montanide ISA 51 (InvivoGen, San Diego, CA)
ondays2and7 postinfection.TheTLRagonistswere administered
s.c. in two separate regions in the interscapular area. Based on
previous studies, we decided to use a fixed standardized dose of
2 mg/animal and 1/mg per animal of poly (I:C) and CL097M-012,
respectively, rather than to adjust the dose based on body weight, as
this dose resulted in the stimulation of innate and/or adaptive
immune responses in rhesus monkeys [30,31,33,35]. Control group
3 (n=4; TLR) received only the TLR agonists as described for
Group 2. Controlgroup 4 (n=3;Control) received 1 ml (s.c. deltoid
area) of supernatant from mock-infected Vero cells.
All procedures were reviewed and approved by the Institute’s
Animal Care and Use Committee at Medical Sciences Campus,
University of Puerto Rico (IACUC-UPR-MSC), and performed in
a facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC). Animal
Welfare Assurance Number: A3421, Protocol number: 7890108.
In addition, steps were taken to ameliorate suffering in accordance
with the recommendations of the Weatherall report, ‘‘The Use of
Non-human Primates in Research’’. For instance, to ameliorate
the suffering of the animals, all procedures were conducted under
anesthesia by using ketamine 10–20 mg/kg IM as approved by
IACUC. Anesthesia was delivered in the caudal thigh using a 23
gauge sterile syringe needle. Continued monitoring was provided
by a trained Veterinarian at the Animal Research Center. During
the time of the protocol, animals were under the Environmental
Enrichment program of the facility, also approved by IACUC.
PBMC Separation
Sera and peripheral blood mononuclear cells (PBMC) were
collected on days 1, 4, 10 and 30 post infection. Cells were
preserved in liquid nitrogen for FACS analysis.
RNA extraction, viremia and DENV NS1 protein detection
RNA was extracted from 400 ml of serum using an RNeasy
Mini Kit (Qiagen, Valencia, CA), and eluted in 30 ml of RNase-
free H2O. The quality and quantity of RNA were determined
using Agilent Bioanalyzer RNA Nanochip technology.
RNA extracted from sequentially collected serum samples in the
first 10 days after infection was used to quantify viremia by Real-
Time RT-PCR (qRT-PCR) using an iQ5 machine (BioRad
Laboratories, Hercules, CA) following previously published
procedures [36]. Results were confirmed in plasma samples by
using the Platelia Dengue NS1 Ag Kit (Bio-Rad, Marnes-la-
Coquette, France) following the manufacturer’s instructions.
Flow cytometric analysis
PBMC (10
6) collected on days 1, 4 and 10 after infection were
stained with anti-human antibodies cross-reactive with rhesus
TLRs-DENV interaction In Vivo
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immunoglobulin as a negative control. These antibodies included
a cocktail of linage-specific antibodies [fluorescein isothiocyanate
(FITC)–conjugated CD3 (clone SP34), CD16 (clone 3G8), CD20
(clone 2H7), CD14 (clone M5E2)] and antibodies used for DC
characterization [peridinin chlorophyll protein (PerCP Cy5.5)-
conjugated CD86 (clone IT2.2), phycoerythrin (PE)-conjugated
CD40 (clone 5C3), Alexa Fluor H700-conjugated HLA-DR (clone
L243), and allophycocyanin (APC)-conjugated CD123 (clone 7G3)
or CD11c (clone S-HCL-3) for pDC and mDC, respectively.
PBMC collected on day 10 and 30 were stained with specific
markers for B cells [FITC-conjugated CD20 (clone 2H700), APC-
conjugated CD3 (clone SPE34-2)]. For activation of these cells a
PE-conjugated anti-CD69 (clone FN50) was used. After 30 min of
incubation at 4uC in the dark, the PBMC were washed with PBS
and 300 mL of 1% formaldehyde was added to fix the samples.
The samples were stored at 4uC in the dark and analyzed within
6 hrs on a BD FACSAria (BD Biosciences). Data were analyzed
using Summit Software (version 3.1). The frequencies of activated
cells are reported as a percentage of the specific cell population.
Antibodies against CD86 and HLA-DR were purchased from
Biolegend (San Diego, CA) and anti-CD69 was obtained from
Dako (Carpentaria, CA). All other antibodies were purchased
from BD Pharmingen (San Jose, CA).
Antibody measurements
Prior to study entry, all animals were tested for the presence of
both anti-Dengue IgM ad IgG. The IgM antibody-capture
enzyme-linked immunosorbent assay (MAC-ELISA) and the
Dengue-IgG antibody tests were performed using a quantitative
in-house ELISA procedure described elsewhere [37].
Neutralizing antibodies were determined in samples collected
30 days after the infection, and antibody isotyping was performed
on serum samples from days 10, 15 and 30. Neutralizing
antibodies were determined by the FACS neutralization test
(FNT) as previously described [38]. An in-house indirect
enzymatic immune assay system was developed for the determi-
nation of DENV-specific IgG classes. A DENV-2 antigen with
known cross-reactivity to all DENV serotypes was used (Fitzgerald
Industries International, Acton, MA). Mouse monoclonal anti-
human IgG1 and IgG2 antibodies (Sigma) were used for subclass
classification. The ratios of DENV-specific IgG subclass antibodies
were calculated with the following formula: ratio = [(OD of
sample - OD of blank) – (average of negative control)]/(OD IgG1/
OD IgG2) and vice versa, where OD is the optical density of each
sample.
Multiplex cytokine/chemokine detection
Serum samples collected on days 1, 4, 10 and 15 after infection
were used to detect the presence of 14 nonhuman primate
chemokines and cytokines [CXCL-10 (IP-10), MIP-1b, TNF-a,G -
CSF, IFN-a, IFN-c, IL-12 (p40), IL-17, IL-18, IL-1b, IL-1Ra, IL-
4, IL-5, IL-6], using the Luminex100 system as previously
described [37]. The raw data (mean fluorescence intensity) from
all the bead combinations tested were analyzed with Master-Plex
QT quantification software (MiraiBio Inc., Alameda, CA) to
obtain concentration values in pg/ml. Baseline values were
determined with samples collected from animals in the control
group at each time point.
Statistical analysis
Values were expressed as mean 6 standard error of the mean
(SEM). Significant differences were determined by Student’s t-test
or the Mann Whitney U-test. Two-way analysis of variance
(ANOVA) tests followed by the Bonferroni multiple comparison
test correction and the Kruskal-Wallis test were used. When
applied, further differences between groups were tested by un-
paired t-tests. Analyses were performed using Prism software
(version 5.0c; GraphPad Software Inc., San Diego, CA). A P value
of ,0.05 was considered to represent a significant difference with
(*) p,0.05, (**) p,0.01, and (***) p,0.001.
Results
Effect of TLR agonists on the outcome of DENV-1
infection
The effectiveness of poly (I:C) and CL097M-012 as agonists for
TLR-3 and TLR-7/8, respectively, to modulate immune
responses in rhesus macaques was previously established in vivo
[31,32,33], including in studies of YF, another member of the
Flaviviridae family [30]. Based on these data, and to facilitate
comparison with previous studies, we used the same doses in the
current studies.
Viremia was detected by qRT-PCR in 2 of 3 animals infected
with DENV, with peak viremia occurring on day 4 after infection
(Fig. 1A, left panel). Interestingly, the viremia was abrogated in 3
of the 4 DENV/TLR animals (75%) and remained at the
minimal level of detection in the other treated animal (25%)
(Fig. 1A, right panel). The results of the viral load assay correlate
with the levels of DENV NS1 protein in plasma (Fig. 1B). Two
animals in the DENV group were equivocal and one was highly
positive for the NS1 viral protein 4 days after infection. The
index value of this group was significantly higher when compared
to the Control group (p,0.018), whereas the 4 DENV/TLR
animals remained negative without a significant difference
compared to the Control group despite being infected with
DENV under similar conditions to animals in the DENV group.
Taken together, administration of combined TLR agonists during
the acute phase of DENV infection was associated with control of
viral replication.
Effect of TLR agonists on the innate immune response in
vivo
To establish a potential contribution of TLR stimulation on
effector cells of the innate immune response after DENV
infection in vivo, we studied the activation of pDC and mDC in
peripheral blood. We examined: (i) day 1 post infection (prior to
TLR stimulation), and (ii) days 4 and 10 post infection
corresponding to 48 and 72 hours after the first and second
TLR administrations, respectively. On day 1 post infection, no
activation of DC compared to day 0 was detected (data not
shown). However, on day 4 post infection, the frequencies of the
activation markers CD40
+ and CD86
+ on mDC were signifi-
cantly higher in the TLR group (4.418% 60.231% SEM)
compared to all other groups (DENV/TLR: 3.66% 60.080%
SEM, p,0.021; DENV: 0.950% 60.320% SEM, p,0.001;
Control: 1.233% 60.190% SEM, p,0.001). Animals in the
DENV/TLR group also showed higher frequencies of activated
mDC when compared to the DENV-infected and Control groups
(Fig. 2A, left panel). No statistically significant differences in the
percentage of activated pDC (Lin
2/HLA-DR
+/CD123
+/
CD40
+/CD86
+) were detected on day 4 post infection between
groups (data not shown).
However, on day 10 post infection (72 hours after the second
administration of TLR agonists), both mDC (Fig. 2A, right panel)
and pDC (Fig. 2B) showed a higher frequency of activation in the
DENV/TLR group when compared to the DENV or Control
groups (for mDC: 3.755% 60.082% SEM vs. DENV 1.810%
TLRs-DENV interaction In Vivo
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p,0.001; for pDC 6.628% 61.244% SEM vs. DENV 1.870%
60.035% SEM p,0.023; and vs. Control 1.980% 60.250% SEM
p,0.026). Animals in the combined TLR group alone had
statistically higher frequencies of activated mDC (Fig. 2A, right
panel), but not of pDC (Fig. 2B), when compared to the Control
group (3.168% 60.384% SEM vs. 1.838% 60.596% p,0.027).
At this later time point, no statistical differences were observed
between the DENV/TLR and TLR groups, reinforcing the anti-
inflammatory response by DENV in the results obtained during
the viremia peak observed on day 4 (Fig. 2A, left panel).
Induction of pro-inflammatory cytokines and
chemokines
Circulating serum levels of cytokines and chemokines were
measured within groups. The levels of CXCL-10 (IP-10) were
significantly higher at day 4 post infection (48 hours after the first
TLR administration) in the TLR group compared to the Control
group (1050 pg/ml 6183.3 SEM vs. 430.6 pg/ml 693.85 SEM,
p,0.043) (Fig. 3A), suggesting that only the TLR agonists, but
not DENV or DENV/TLR, induced the secretion of this
chemokine in significant amounts compared to the Control
group. Seventy-two hours after the secondary TLR stimulation
(day 10), serum levels of CXCL-10 remained higher than those of
the Control group, yet not statistically significant (data not
shown).
Serum levels of IL1-Ra experienced a surge on day 4 after the
infection in all groups that received the TLR agonists (Fig. 3B). Of
interest, the levels of this cytokine were significantly higher in the
TLR group when compared to the DENV or DENV/TLR groups
(366.0 pg/ml 638.41 SEM vs. 39.20 pg/ml 65.725 SEM
p,0.008 and vs. 177.1 pg/ml 637.15 SEM p,0.012, respective-
ly). Meanwhile, the values of serum IL-1Ra in the DENV/TLR
group were also significantly higher than in the DENV group
(177.1 pg/ml 637.15 SEM vs. 39.20 pg/ml 65.725 SEM
p,0.063). Serum levels of this cytokine continued to increase
consistently by day 10, and remained elevated on day 15 post
infection in the groups receiving TLRs (Fig. 3B).
We did not detect significant changes of any of the other 12
cytokines or chemokines tested, including IFN-a, IFN-c, TNF-a
and IL-12p40 among others (data not shown). Taken together, the
data indicate that both CXC10 and IL-1Ra are major
components of the inflammatory response induced by TLR
activation but not by Dengue infection alone in rhesus macaques.
Figure 1. Toll-like receptor agonists abrogate viremia. A: Left panel, a peak of viremia was detected at day 4 after DENV infection in two of
three animals (44Z and AM28). However, this peak was completely absent in the four animals of the DENV/TLR group at 48 hours after the TLR3 and
7/8 agonists [poly (I:C) and CL097M-012, respectively] were administered (right panel). Results are expressed in milliequivalent genomes per milliliter.
B: Plasma levels of DENV protein NS1 were not significantly different between the DENV group and the treated group (DENV/TLR). However, NS1
levels were significantly higher in the DENV group compared to the Control group (p,0.018), whereas they were not significantly different between
the DENV/LTR (despite the Dengue infection) and the Control groups. This confirmatory assay corroborates the role of TLRs in controlling DENV
replication. The results reflect the ratio of the sample O.D./Control O.D. according to the manufacturer’s instructions.
doi:10.1371/journal.pone.0019323.g001
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immune response to DENV
Activated B cells, defined as CD20
+/CD3
2/CD69
+, were
detected on day 10 post infection (72 hours after secondary TLR
stimulation) (Fig. 4A). Animals in the DENV/TLR group had the
highest frequencies of activated B cells, and this difference reached
statistical significance compared to the DENV group, (3.460%
60.028% SEM vs. 2.177% 60.422% SEM, p,0.015), the TLR
group (3.460% 60.028% SEM vs. 1.260% 60.117% SEM,
p,0.060), and the Control group (3.460% 60.028% SEM vs.
1.073% 60.085% SEM, p,0.001). Animals infected with DENV
group did not differ in their frequencies of activated B cells from
animals in the TLR group (2.177% 60.422% SEM vs. 1.260%
60.117% SEM p=0.06), or the Control group (1.073% 60.085%
SEM, p=0.06) (Fig. 4A).
To test whether these differences in the frequencies of activated
B cells translated into differences in antibody responses, we
measured the level of total anti-DENV-specific antibodies in all
groups. As shown in Fig. 4B, one month after the infection, DENV
antibodies were significantly higher in the DENV/TLR group
compared to the DENV group (p,0.02). We then tested whether
TLR administration impacted antibody isotype switching. Serum
samples were collected on days 10, 15 and 30 post infection from
animals in the DENV/TLR and DENV groups and analyzed for
DENV-specific IgG1 and IgG2 isotypes.
Surprisingly, and despite being still very low at the early time
point of 10 days post infection, the levels of anti-DENV IgG1 were
significantly lower in the DENV/TLRs group compared to
DENV animals (p,0.014) (Fig. 4C). Significantly lower levels of
IgG1 were also observed on day 30 post infection (p,0.007). A
strong trend to higher values of IgG2 was observed in the DENV/
TLR group, but did not reach statistical significance compared to
the DENV group. However, this differential regulation of IgG
isotypes resulted in a significantly higher IgG2/IgG1 ratio in the
DENV/TLR group compared to the DENV group on days 10
(p,0.001) and 30 (p,0.017) after the infection (Fig. 4D).
Thirty days after the infection, neutralizing antibodies showed a
trend to be higher in animals administered TLR/DENV
Figure 2. Dengue virus inhibits TLR-induced activation of mDC. A: Left panel, 48 hours after the first TLR stimulation, mDC were activated in
the groups receiving TLRs but not in the group receiving only the virus. Coincident with the peak of viremia at day 4, an inhibitory effect of DENV on
the mDC subset was evidenced by the frequency of activated cells in the DENV group, which was significantly lower compared to the DENV/TLR and
TLR groups. Right panel, 10 days after the infection (72 hours after second TLR stimulation) the mDC subset was still significantly activated in both
groups that received TLRs when compared to the Control group. However, the inhibitory effect of DENV was absent as there were no significant
differences between the DENV and DENV/TLR groups, supporting the role of DENV replication in the inhibitory effect on mDC activation on day 4. B:
Ten days after infection and 72 hours after the secondary TLR stimulation the frequency of activated pDC was significantly higher in the DENV/TLR
and TLR groups compared to the DENV and Control groups. However, an inhibitory effect of DENV on this subset of DC was not observed. Asterisks
denote significant differences, (*) p ,0.05, (**) p ,0.01, and (***) p,0.00.
doi:10.1371/journal.pone.0019323.g002
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no shown).
Discussion
Dengue is an acute illness in which symptoms are present before
full activation of the adaptive immune response takes place. The
early recognition of virus infection by the innate immune system
plays a critical role in priming and regulating the adaptive immune
response. TLRs, which are especially abundant on effector cells of
the innate immune response (macrophages, DC), are important in
the initiation, shaping and regulation of the inflammatory response
against viral diseases [39,40]. Recently, it was shown that DENV
differentially regulates several TLRs at the transcriptional level [6].
However, understanding the role of TLRs in the innate
recognition and modulation of the adaptive immune response to
DENV had not progressed due to the limitations of in vivo models
for Dengue. We now provide evidence to support the hypothesis
that maintenance of TLR-mediated responses, which are other-
wise potentially countered by Dengue infection, may allow for
greater control of viral replication.
Previously, it was shown that administration of multiple
intravenous (i.v.) doses of the TLR3 agonist poly (ICLC) delayed
the viremia in rhesus macaques infected with YF [30] and
eliminated or delayed the viremia in animals challenged with VEE
virus [31]. This effect on viremia was associated with the detection
of IFN-a. Although, poly (I:C) is known to be a poor inducer of
IFN-a in humans [41] and in non-human primates [33,34], there
are no available data on the impact of poly (I:C) on viremia in
non-human primates and we did not identify a report on the effect
of CL097M-012 (TLR-7/8 agonist) on any virus replication in vivo.
However, our data are consistent with the YF and VEE reports, as
in vivo administration of both TLR3 [poly (I:C)] and TLR-7/8
(CL097M-012) agonists at 48 hours after Dengue virus infection
decreased viremia in 100% of the treated animals (Fig. 1B). To
confirm the viremia results measured by qRT-PCR, we used the
Platelia Dengue NS1 Ag Kit because it allowed us to measure NS1
protein in plasma samples and because of its high sensitivity (66%)
and specificity (100%), as recently reported in tests of more than
800 samples from patients from Asia and Latin America [42]. In
addition, this kit showed higher sensitivity (88%) in detecting
DENV-1 than the other three DENV serotypes [42].
Induction of type-I IFN is expected to be associated with an
anti-viral effect, although we were unable to detect type-I IFN in
serum at any time point assayed after infection/stimulation (see
below). A high clearance rate for circulating levels of type-I IFN
may be associated with our failure to detect it, and future studies
may need to collect samples closer to the time of TLR
administration.
To delineate the contribution of innate effectors cells on the
immune response, the frequencies of activated peripheral pDC
and mDC were ascertained. Four days after DENV infection (48
hours after the first TLR administration), the highest level of mDC
activation was observed in the TLR group whereas DENV
infection alone did not result in activation of these cells (Fig. 2A,
left panel), supporting the conclusion that TLR induction can
overcome a virus-induced lack of innate activation responses in the
presence of viremia.
Indeed, a negative effect of DENV infection on mDC
activation was shown by the fact that animals in the DENV/
TLR group had frequencies of activated mDC that were in
between the values seen for animals in the DENV group and
animals in the TLR group (Fig. 2A, left panel). This observed
effect of DENV-mediated suppression of mDC activation is
consistent with prior in vitro studies [23,24,43] and thus provides a
link to in vitro effects within an in vivo model of infection. It is of
interest to speculate whether this lack of mDC activation after
infection may contribute to a decrease in adaptive immune
responses. Notably, 10 days after the infection, animals in the
DENV/TLR group showed higher frequencies of activated pDC
when compared to the Control and DENV groups (Fig. 2B),
suggesting that activation of DC is related to control of DENV
(Fig. 1). Our results confirm previous finding showing that a
blunted blood pDC response to dengue virus infection was
Figure 3. Serum levels of CXCL-10 and IL-1Ra are increased
significantly after TLR stimulation and are inhibited by DENV.
A: Coincident with the higher level of mDC activation, serum levels of
CXCL-10 increased significantly only in the TLR group when compared
to the Control group. Higher levels, albeit not significant, were also
found in the DENV/TLR group. The lowest levels among the
experimental groups were found in animals of the DENV group. This
trend in the serum levels of CXCL-10 among different groups confirms a
stimulatory effect of the TLR agonist but at the same time suggests an
inhibitory role of Dengue virus in the secretion of this cytokine.
B: Serum levels of IL-1Ra peaked 48 hours after the first TLR stimulation.
An inhibitory effect of DENV at this time point (also coincident with the
viremia peak) is supported by significantly higher values of this cytokine
in the TLR group when compared to the DENV and DENV/TLR groups.
Both groups, DENV/TLR and TLR, showed significantly higher serum
levels of this cytokine when compared to the DENV and Control groups.
Ten days after the infection (72 hours after second TLR stimulation), IL1-
Ra values were still increased in both groups receiving TLR agonists.
Significantly higher levels were present up to 15 days after the infection
(8 days after the last TLR stimulation). However, at the later time point,
there was no significant difference between the DENV/TLR and TLR
groups. Asterisks denote significant differences, (*) p ,0.05,
(**) p,0.01, and (***) p,0.001.
doi:10.1371/journal.pone.0019323.g003
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cascade leading to severe disease [27].
Importantly, our in vivo data are consistent with previous in vitro
findings demonstrating that DENV infection antagonizes the effect
of the TLR-3 agonist poly (I:C) on DC activation (Fig. 2A,
DENV/TLR vs. TLR group, p,0.021) [23,44]. The mechanisms
used by the virus to interfere with TLR signaling pathways require
further investigation. However, we have evidence showing that
DENV is able to block the activation and nuclear translocation of
IRF3, a key player in the TLR3 pathway, induced by the agonists
TLR3 poly (I:C) and LyoVec (Anglero, Y et al., unpublished
results). The blockage of the activation of this regulatory factor by
DENV after poly (I:C) treatment has been recently confirmed in
vitro by others [44].
Furthermore, the inhibition of CXCL-10 secretion and of IL-
1Ra by DENV is consistent with the profile of mDC deactivation,
and emphasizes the potential role of DENV in suppressing TLR-
induced inflammation. There are previous reports showing that
poly (I:C) induces the activation of rhesus monkey DC in vitro [45]
and that CXCL-10 levels in serum are mainly produced by DC
after TLR-3 agonist stimulation [34]. Other in vitro studies have
confirmed that DC produced CXCL-10 after DENV infection
[21,23,46], but that its secretion was markedly reduced in DENV-
infected cells when compared to non-infected bystander cells
[21,23]. Our present study shows concordance between TLR
stimulation, DC activation (Fig. 2A left panel), CXCL-10
induction (Fig. 3A), and an immune response associated with
control of DENV, whereas DENV alone is expected to act against
these responses. In mouse models of DENV infection, it has been
shown that CXCL-10 is required for resistance to primary DENV
infection [47] by competitive inhibition of viral binding to heparan
sulfate, the natural receptor of this virus.
The role of IL-1Ra in the pathogenesis of DENV is not fully
understood. In one report, studying a cohort of 50 children, high
levels of this cytokine were associated with high mortality [48], but
in another report, high plasma levels of IL-1Ra were detected only
Figure 4. TLR3-7/8 stimulations in synergism with DENV induce quantitative and qualitative modifications of the humoral
response. A: Ten days after the infection, the frequency of activated B cells was significantly higher in DENV/TLR group when compared to all other
groups, showing a synergistic effect of DENV with the TLR agonists in this activation. DENV alone was able to induce activation of B cells when
compared to the TLR and Control groups. However, in our model, TLR agonists alone were not sufficient to induce B-cell activation. B: The activation
profile of B cells correlates with the levels of anti-DENV antibodies. Antibody levels were significantly higher in the DENV/TLR group compared to the
DENV group. C: As early as 10 days after infection and coincident with activation of B cells, the switch to IgG1 was significantly diminished in the
DENV/TLR group. This difference had disappeared by 15 days after the infection, but it was re-established on day 30. D: Although antibody O.D.
values were limited, the difference in the IgG1 and IgG2 levels translated into a significant increase of the IgG2/IgG1 ratio (.11 and 6 times on days
10 and 30 after the infection, respectively). Asterisks denote significant differences, (*) p,0.05, (**) p,0.01, and (***) p,0.001.
doi:10.1371/journal.pone.0019323.g004
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symptoms [49]. Recently, transcriptional up-regulation of the IL-
1Ra gene was associated with pleural effusion in a cohort of
children with suspected diagnosis of DHF/DSS [6].
Compared to changes in IL1-Ra or CXCL-10, the pro-
inflammatory cytokines are relatively short-lived and elevated
concentrations are found only soon after the onset of serious
infections [50], which could explain why we did not detect any of
the other tested pro-inflammatory cytokines. Indeed, as our first
sample collection was made 48 hours after the first TLR
stimulation, we probably would have missed a transient peak in
cytokine release that might have occurred before that time.
Nevertheless, our results confirm a previous report in which no
significant differences in serum levels of IFN-a, IFN-c, TNF-a,
IL12p40 and CCL3 were observed at 6, 24 or 48 hours between
groups of rhesus macaques receiving the adjuvant KLH alone or
together with poly (I:C) [34]. The absence of type-I IFN
production after DENV infection in vivo reported in this work
was first noticed by our group [28] and it has been confirmed
recently in vitro in humans DC [44,51].
Finally, we aimed to correlate differences in the innate responses
observed between the various experimental groups to differences
in DENV-specific immune responses. In recent years, there has
been accumulating evidence that TLR agonists can directly
activate B cells, promoting cell proliferation and IgG isotype
switching [52,53,54]. In addition to B-cell activation, we also
demonstrated a significant reduction of IgG1 concurrent with an
increase of IgG2 antibodies (Fig. 4C). Our data are consistent with
a report demonstrating that signaling through MyD88 (in our case
stimulated by the TLR-7 agonist CL097M-012) may negatively
regulate IgG1 and promote IgG2a/c antibodies [55].
The synergistic effect of TLRs with DENV infection on
switching antibodies described in this work is of particular interest
for DENV pathogenesis as it has been shown that IgG1 can fix
complement more effectively than IgG2 [56,57], thereby contrib-
uting to the development of DHF/DSS [58,59]. The role of IgG1
in both the development and as a prognostic marker of severe
clinical forms after DENV infection has been clearly demonstrated
before [60]. Thus, TLR agonists can affect the type of antibody
response that prevails after infection by eliciting a higher ratio of
IgG2 to IgG1.
To our knowledge, this work presents the first data on the role
of TLRs in the proliferation, activation and maturation of B-cell
isotypes after DENV infection (or any other viral infection) in a
higher animal model. Despite the limitation in the number of
animals per group, our study provides definitive proof-of-concept
data for how the innate response against DENV infection
influence the molecular basis of the DENV–host interaction, from
PRRs to the adaptive immune response, in an animal model, as
well as insights into the mechanism by which DENV evades
immune recognition and activation in vivo. Results from our work
may have implications for the design of anti-DENV vaccine
strategies through the potential use of TLR agonists as vaccine
adjuvants or the exploration of activating TLR responses during
active viremia as a strategy to modulate infection outcomes in vivo.
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